The technology, called contrast-enhanced harmonic endoscopic ultrasound (CH-EUS), is primed to open pathways for more innovative and timely diagnosis and treatment of liver disease, the companies said.

CH-EUS is the use of a contrast agent containing microbubbles and an endoscopic ultrasound system designed to allow the detection of microbubbles within the vasculature, with the intent to provide a more detailed view of potential pathology.

Under terms of the agreement, Olympus will co-market Bracco Diagnostic's Lumason ultrasound-enhancing agent.